Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Completed

Conditions studied: Breast Cancer

In brief

RATIONALE: Studying samples of urine in the laboratory from women with breast cancer may help doctors learn whether tamoxifen and aromatase inhibitors alter the metabolism of estrogens. PURPOSE: This clinical trial is studying the effect of tamoxifen or an aromatase inhibitor on estrogen metabolism in women undergoing treatment for newly diagnosed breast cancer.

Key facts

Study ID

NCT00569543

Run by

University of Nebraska

People needed

27

Starts

2005-05-11

Expected to finish

2012-08-02

Last updated by the study team

2023-09-01

Who can join

Age: 19 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed ductal carcinoma in situ or invasive breast cancer
• Scheduled to receive tamoxifen citrate or an aromatase inhibitor
• Estrogen receptor or progesterone receptor positive
• ECOG performance status 0, 1, or 2

You may not qualify if…

• Not pregnant or nursing
• No prior antiestrogen drug such as tamoxifen citrate or raloxifene
• No concurrent estrogens

Where it is running

• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Eppley Cancer Center at University of Nebraska Medical Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.